Compounds & interventions

Semaglutide

Medicine & Biotech · covered by 52 outlets this week · tracked since 2026-10-27

Press: 46 mainstream 95 specialist 19 independent outlet-days

What it is

Evidence 10/10 · thoroughly established Uneven · 2–10 by use Signals · regulator warning

Semaglutide is a GLP-1 receptor agonist sold as Ozempic (for type 2 diabetes), Wegovy (for weight loss) and Rybelsus (an oral tablet), made by Novo Nordisk. It produced about 15 percent weight loss in trials and has since shown benefits for heart disease, kidney disease and knee osteoarthritis. Coverage centres on who should take it, cost and shortages, compounded and counterfeit versions, muscle loss during rapid weight loss, and what happens when people stop.

The score describes type 2 diabetes (approved 2017), obesity (2021) and cardiovascular risk reduction (2024). The MASH liver indication is new (2025), and uses in alcohol use disorder and dementia are still in trials.

Evidence by use or claim · 1 preclinical to 10 thoroughly established

  1. Type 2 diabetes10/10 · thoroughly established

    Approved in 2017 after the SUSTAIN trials.

  2. Obesity and weight management10/10 · thoroughly established

    Approved in 2021 after the STEP trials.

  3. Cardiovascular risk reduction9/10 · thoroughly established

    SELECT trial; label indication in 2024.

  4. Chronic kidney disease in type 2 diabetes9/10 · thoroughly established

    FLOW trial (2024); label indication in 2025.

  5. MASH (fatty liver disease)7/10 · established for some uses

    Approved in 2025 on biopsy results from the ESSENCE trial; outcome data pending.

  6. Alcohol use disorder3/10 · early human evidence

    One small phase 2 trial reported in 2025; larger trials under way.

  7. Alzheimer's disease2/10 · preclinical

    The EVOKE trials missed their primary endpoint in 2025.

  • RegulatorUS label carries a boxed warning for thyroid C-cell tumours, based on rodent data; contraindicated with a personal or family history of medullary thyroid cancer. source
  • TrialObserved in trials and follow-up: gallstones, early worsening of diabetic retinopathy with fast glucose lowering, a small rise in resting heart rate, and rare pancreatitis. source
  • TrialA rare optic-nerve stroke (NAION) was flagged in 2024 to 2025 observational studies; the European regulator listed it as a very rare side effect in 2025.
  • RegulatorCounterfeit Ozempic reached Europe and the US in 2023, some containing insulin; the FDA issued a counterfeit warning in December 2023. source
  • MarketCompounded semaglutide salts are sold widely online; the FDA says they have not been shown to be safe or effective. source

This week · The FDA required a label warning on all GLP-1 drugs, including semaglutide, about NAION, a rare optic nerve condition; in Brazil the first generic semaglutide pens went on sale after the patent expired.

Written by the Alivewire editors from the coverage below, 3d ago; rated 2d ago. Not medical advice; how the ratings work.

Coverage